Sara M Tolaney

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA
    Invest New Drugs 33:1108-14. 2015
  2. doi request reprint Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
    Sara Tolaney
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
    Breast Cancer Res Treat 149:151-61. 2015
  3. doi request reprint New HER2-positive targeting agents in clinical practice
    Sara Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA
    Curr Oncol Rep 16:359. 2014
  4. ncbi request reprint Follow-up care of patients with breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA
    Breast 16:S45-50. 2007
  5. ncbi request reprint Sarcoidosis mimicking metastatic breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Breast Cancer 7:804-10. 2007
  6. doi request reprint Lymphopenia associated with adjuvant anthracycline/ taxane regimens
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 8:352-6. 2008
  7. ncbi request reprint Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  8. pmc A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer Med 3:293-9. 2014
  9. doi request reprint Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Kathryn J Ruddy
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
    Breast Cancer Res Treat 141:421-7. 2013
  10. doi request reprint Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction
    Kari Joanne Kansal
    Brigham and Women s Hopspital, Boston, MA, USA
    Breast Cancer Res Treat 141:255-9. 2013

Detail Information

Publications20

  1. doi request reprint Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA
    Invest New Drugs 33:1108-14. 2015
    ..We conducted a phase 2 study of tivantinib monotherapy in patients with metastatic triple-negative breast cancer...
  2. doi request reprint Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
    Sara Tolaney
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
    Breast Cancer Res Treat 149:151-61. 2015
    ..Pilaralisib in combination with trastuzumab with or without paclitaxel had an acceptable safety profile in metastatic HER2-positive breast cancer, with clinical activity in the paclitaxel arm...
  3. doi request reprint New HER2-positive targeting agents in clinical practice
    Sara Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA
    Curr Oncol Rep 16:359. 2014
    ..These exciting advances in drug development for HER2-positive breast cancer have also led to many challenges, including how to optimally sequence and combine HER2-targeted agents. ..
  4. ncbi request reprint Follow-up care of patients with breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA
    Breast 16:S45-50. 2007
    ..With the growing number of breast cancer survivors, further studies should be undertaken to study the cost-effectiveness of surveillance strategies...
  5. ncbi request reprint Sarcoidosis mimicking metastatic breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Breast Cancer 7:804-10. 2007
    ..We describe 3 patients who presented with locally advanced breast cancer and who were found to have pulmonary findings for metastatic disease that were proven upon biopsy to be consistent with sarcoidosis...
  6. doi request reprint Lymphopenia associated with adjuvant anthracycline/ taxane regimens
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 8:352-6. 2008
    ....
  7. ncbi request reprint Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  8. pmc A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer Med 3:293-9. 2014
    ..Preoperative capecitabine is a well-tolerated regimen, but appears not lead to pCR when used as monotherapy in HR+ breast cancer...
  9. doi request reprint Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Kathryn J Ruddy
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
    Breast Cancer Res Treat 141:421-7. 2013
    ....
  10. doi request reprint Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction
    Kari Joanne Kansal
    Brigham and Women s Hopspital, Boston, MA, USA
    Breast Cancer Res Treat 141:255-9. 2013
    ..As larger data sets become available with the use of neoadjuvant bevacizumab with mastectomy, further refinement may be necessary. ..
  11. pmc A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
    Joyce F Liu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 49:2972-8. 2013
    ..We investigated the toxicities and recommended phase 2 dosing (RP2D) of the combination of cediranib, a multitargeted inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3 and olaparib, a PARP-inhibitor (NCT01116648)...
  12. doi request reprint Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 112:14325-30. 2015
    ..This study implicates pretreatment MVD as a potential predictive biomarker of response to bevacizumab in BC and suggests that new therapies are needed to normalize vessels without pruning. ..
  13. pmc Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women
    Harold J Burstein
    Harold J Burstein, William T Barry, Sara M Tolaney, and Eric P Winer, Dana Farber Cancer Institute, Boston, MA Constance T Cirrincione, Duke University Alliance Statistics and Data Center Kimberly L Blackwell, Duke University Medical Center, Durham, NC Helen K Chew, University of California, Davis, Davis, CA Diana E Lake and Clifford A Hudis, Memorial Sloan Kettering Cancer Center, New York, NY and Cynthia Ma, Washington University School of Medicine, St Louis, MO
    J Clin Oncol 32:3959-66. 2014
    ..CALGB 40302 sought to determine whether lapatinib would improve progression-free survival (PFS) among women with hormone receptor-positive metastatic breast cancer treated with fulvestrant...
  14. ncbi request reprint Mechanisms of trastuzumab resistance in breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Agents Med Chem 9:348-55. 2009
    ..In this review, we discuss the mechanisms of antitumor activity of trastuzumab, potential mechanisms contributing to its resistance, and novel therapeutic agents that may provide a means to overcome trastuzumab resistance...
  15. doi request reprint Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
    Shom Goel
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA Electronic address
    Cancer Cell 29:255-69. 2016
    ..In vivo, CDK4/6 inhibitors sensitize patient-derived xenograft tumors to HER2-targeted therapies and delay tumor recurrence in a transgenic model of HER2-positive breast cancer. ..
  16. doi request reprint Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors
    Adrienne G Waks
    Dana Farber Cancer Institute, Boston, MA, USA
    Breast Cancer Res Treat 154:359-67. 2015
    ..Replacing dexamethasone with alternative anti-emetics may mitigate this risk. ..
  17. doi request reprint The evolving understanding of small HER2-positive breast cancers: matching management to outcomes
    Adrienne G Waks
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Future Oncol 11:3261-71. 2015
    ..The landscape of next generation anti-HER2 therapies is quickly evolving; a role for some of these agents in the small HER2-positive subpopulation may also be on the horizon...
  18. pmc Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A
    WILLIAM M SIKOV
    William M Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI Donald A Berry, University of Texas MD Anderson Cancer Center, Houston, TX Charles M Perou and Lisa A Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill Constance T Cirrincione, Alliance Statistical Center, Durham Charles S Kuzma, Southeast Cancer Control Consortium, Winston Salem, NC Baljit Singh, New York University Medical Center Elisa R Port, Mount Sinai Medical Center Clifford A Hudis, Memorial Sloan Kettering Cancer Center, New York, NY Sara M Tolaney, Mehra Golshan, Jennifer R Bellon, and Eric P Winer, Dana Farber Cancer Institute, Boston, MA Timothy J Pluard, Washington University St Louis Medical Center, St Louis, MO George Somlo, City of Hope Comprehensive Cancer Center, Duarte Deborah Collyar, Patient Advocates In Research, Danville, CA and Olwen M Hahn, University of Chicago Medical Center, Chicago, IL
    J Clin Oncol 33:13-21. 2015
    ..CALGB 40603 (Alliance), a 2 × 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevacizumab...
  19. pmc Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
    Sara M Tolaney
    From the Departments of Medical Oncology S M T, B A O, A H P, I E K, H J B, E P W and Biostatistics and Computation Biology W T B, H G, Dana Farber Cancer Institute, and Department of Hematology Oncology, Massachusetts General Hospital B M both in Boston Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York C T D, C A H, and Department of Medical Oncology, Hofstra North Shore LIJ School of Medicine, New Hyde Park I S all in New York Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville D A Y Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham P K M, and Department of Medical Oncology, University of North Carolina, Chapel Hill L A C both in North Carolina Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL K S A Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco H S R Department of Medical Oncology, Washington University in St Louis, 3400 Spruce Street
    N Engl J Med 372:134-41. 2015
    ....
  20. pmc Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer
    Judy E Garber
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Cancer Inst 102:942-9. 2010
    ..We investigated whether FVL was associated with TE risk in women with early-stage breast cancer who took adjuvant tamoxifen...